We are live on
!
Find out more
MCM
Marathon Capital Management Portfolio holdings
AUM
$494M
1-Year Est. Return
42.6%
This Fund
S&P 500
This Quarter
Est. Return
+6.01%
1 Year Est. Return
+42.6%
3 Year Est. Return
+70.91%
5 Year Est. Return
+55.81%
10 Year Est. Return
+429.8%
AUM
$398M
AUM Growth
+$456K
(+0.11%)
Cap. Flow
-$15M
Cap. Flow
% of AUM
-3.78%
Top 10 Holdings %
Top 10 Hldgs %
43.03%
Holding
164
New
6
Increased
27
Reduced
86
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$6.19M |
| 2 |
Diamondback Energy
FANG
|
+$5.29M |
| 3 |
Allison Transmission
ALSN
|
+$1.27M |
| 4 |
Copa Holdings
CPA
|
+$577K |
| 5 |
Nabors Industries
NBR
|
+$485K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Transocean
RIG
|
+$8.76M |
| 2 |
T. Rowe Price
TROW
|
+$3.93M |
| 3 |
Bank of Montreal
BMO
|
+$2.53M |
| 4 |
HDSN
Hudson Technologies
HDSN
|
+$1.85M |
| 5 |
Blue Bird Corp
BLBD
|
+$1.56M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 32.13% |
| 2 | Technology | 17.5% |
| 3 | Industrials | 12.92% |
| 4 | Healthcare | 10.38% |
| 5 | Energy | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
T. Rowe Price
TROW
$25B
| $93.6M | 23.52% |
868,792
-39,487
| -4% | -$3.93M |
|
2
Apple
AAPL
$4.88T
| $11.3M | 2.83% |
58,576
+215
| +0.4% | +$39.7K |
|
3
Microsoft
MSFT
$2.85T
| $9.53M | 2.4% |
25,346
-470
| -2% | -$167K |
|
4
Enphase Energy
ENPH
$4.89B
| $9.42M | 2.37% |
71,286
+30
| +0% | +$3.18K |
|
5
Qualcomm
QCOM
$176B
| $8.67M | 2.18% |
59,965
-1,204
| -2% | -$149K |
|
|
HDSN
6
Hudson Technologies
HDSN
$267M
| $8.2M | 2.06% |
608,100
-143,050
| -19% | -$1.85M |
|
|
7
Allison Transmission
ALSN
$10.1B
| $7.93M | 1.99% |
136,339
+22,735
| +20% | +$1.27M |
|
8
MetLife
MET
$60.6B
| $7.75M | 1.95% |
117,124
+107
| +0.1% | +$6.7K |
|
9
Hillman Solutions
HLMN
$1.56B
| $7.55M | 1.9% |
819,225
-102,625
| -11% | -$783K |
|
10
Corning
GLW
$126B
| $7.29M | 1.83% |
239,393
-2,975
| -1% | -$85.1K |
|
11
IBM
IBM
$203B
| $7.03M | 1.77% |
42,964
-362
| -0.8% | -$54.7K |
|
12
Chevron
CVX
$389B
| $6.78M | 1.71% |
45,479
-427
| -0.9% | -$64.6K |
|
|
13
AstraZeneca
AZN
$262B
| $6.41M | 1.61% |
+47,595
| New | +$6.19M |
|
|
14
Copa Holdings
CPA
$5.57B
| $6.41M | 1.61% |
60,273
+6,310
| +12% | +$577K |
|
|
15
Diamondback Energy
FANG
$57.8B
| $6.31M | 1.59% |
40,690
+33,750
| +486% | +$5.29M |
|
|
DOC
16
DELISTED
PHYSICIANS REALTY TRUST
DOC
| $6.06M | 1.52% |
455,584
-7,611
| -2% | -$90.4K |
|
17
Identive
INVE
$64.6M
| $5.9M | 1.48% |
716,324
-27,427
| -4% | -$194K |
|
18
Bristol-Myers Squibb
BMY
$127B
| $5.86M | 1.47% |
114,134
-6,593
| -5% | -$346K |
|
19
TETRA Technologies
TTI
$1.24B
| $5.86M | 1.47% |
1,295,445
-146,675
| -10% | -$740K |
|
20
Fidelity National Information Services
FIS
$21.5B
| $5.69M | 1.43% |
94,761
-16,582
| -15% | -$910K |
|
21
Willis Towers Watson
WTW
$27.8B
| $4.86M | 1.22% |
20,153
-220
| -1% | -$50.9K |
|
22
Berkshire Hathaway Class B
BRK.B
$1.06T
| $4.54M | 1.14% |
12,740
+324
| +3% | +$114K |
|
23
Delta Air Lines
DAL
$55.7B
| $4.53M | 1.14% |
112,602
-858
| -0.8% | -$31.1K |
|
24
Johnson & Johnson
JNJ
$634B
| $4.48M | 1.13% |
28,560
+176
| +0.6% | +$27K |
|
|
MRO
25
DELISTED
Marathon Oil Corporation
MRO
| $4.21M | 1.06% |
174,160
+4,854
| +3% | +$125K |
|
Similar funds
LI
SAS
BFIC
BPIA
FSA
TAM
CH
NHT
Marathon Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Marathon Capital Management held 164 positions worth $398M, up 0.11% from $397M the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Marathon Capital Management withdrew a net $15M in Q4 2023, closing 11 positions and reducing 86 holdings. Its most notable exit was iShares iBonds Dec 2023 Term Treasury ETF, an estimated $819K position sold in full.
By sector, the portfolio is most concentrated in Financials at 32% of assets, down from 32% a quarter earlier, followed by Technology and Industrials.
Against the trend, Marathon Capital Management opened a new position in AstraZeneca worth $6.41M.
- Marathon Capital Management's largest Q4 2023 buy was AstraZeneca: 47,595 shares worth $6.41M.
- Marathon Capital Management added most to Diamondback Energy in Q4 2023, an estimated $5.29M increase.
- Marathon Capital Management's biggest Q4 2023 reduction was Transocean, cutting an estimated $8.76M.
- Marathon Capital Management fully exited iShares iBonds Dec 2023 Term Treasury ETF in Q4 2023, selling an estimated $819K.
- Marathon Capital Management's ten largest holdings make up 43% of its $398M portfolio in Q4 2023.
- Marathon Capital Management opened 6 new positions and closed 11 in Q4 2023.
- Marathon Capital Management's portfolio value rose 0.11% quarter-over-quarter to $398M.
Based on Marathon Capital Management's 13F filing for Q4 2023, filed 8 Feb 2024.